{"nctId":"NCT04887948","briefTitle":"Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2","startDateStruct":{"date":"2021-05-20","type":"ACTUAL"},"conditions":["Pneumococcal Disease","COVID-19","SARS-CoV-2 Infection"],"count":570,"armGroups":[{"label":"Coadministration Group","type":"EXPERIMENTAL","interventionNames":["Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)","Biological: BNT162b2"]},{"label":"20vPnC-only Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)","Other: Saline"]},{"label":"BNT162b2-only Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: BNT162b2","Other: Saline"]}],"interventions":[{"name":"20-valent pneumococcal conjugate vaccine (20vPnC)","otherNames":[]},{"name":"BNT162b2","otherNames":[]},{"name":"Saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female participants ≥65 years of age at the time of consent\n* Participating or participated in Study C4591001, received 2 doses of 30 µg BNT162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of BNT162b2\n* Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease\n* Adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study\n\nExclusion Criteria:\n\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)\n* Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study\n* Previous clinical or microbiological diagnosis of COVID-19\n* Previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation\n* Previous vaccination with any coronavirus vaccine, other than those received in Study C4591001\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\\>) 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm and severe: \\>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at each injection site within 10 days after vaccination and the associated 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"9.7","spread":null},{"groupId":"OG002","value":"8.1","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"9.7","spread":null},{"groupId":"OG005","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"4.3","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"6.5","spread":null},{"groupId":"OG005","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"3.2","spread":null},{"groupId":"OG002","value":"3.2","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"2.7","spread":null},{"groupId":"OG005","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.5","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.5","spread":null},{"groupId":"OG005","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"9.7","spread":null},{"groupId":"OG002","value":"8.6","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"11.4","spread":null},{"groupId":"OG005","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"5.4","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"6.5","spread":null},{"groupId":"OG005","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"3.2","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"4.9","spread":null},{"groupId":"OG005","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"72.4","spread":null},{"groupId":"OG002","value":"60.2","spread":null},{"groupId":"OG003","value":"9.7","spread":null},{"groupId":"OG004","value":"67.6","spread":null},{"groupId":"OG005","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":null},{"groupId":"OG001","value":"56.8","spread":null},{"groupId":"OG002","value":"52.2","spread":null},{"groupId":"OG003","value":"9.7","spread":null},{"groupId":"OG004","value":"50.3","spread":null},{"groupId":"OG005","value":"16.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"15.7","spread":null},{"groupId":"OG002","value":"7.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"17.3","spread":null},{"groupId":"OG005","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.1","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events including fever, fatigue, headache, chills, muscle pain and joint pain were recorded by participants using an e-diary. Fever was defined as temperature \\>=38.0 degree Celsius (C) and categorized as \\>=38.0 to 38.4 degree C, \\>38.4 to 38.9 degree C, \\>38.9 to 40.0 degree C and \\>40.0 degree C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Percentage of participants with systemic events within 7 days after vaccination and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null},{"groupId":"OG001","value":"36.0","spread":null},{"groupId":"OG002","value":"54.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"23.7","spread":null},{"groupId":"OG002","value":"27.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":null},{"groupId":"OG001","value":"12.4","spread":null},{"groupId":"OG002","value":"24.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"17.2","spread":null},{"groupId":"OG002","value":"33.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"14.5","spread":null},{"groupId":"OG002","value":"24.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"2.7","spread":null},{"groupId":"OG002","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"7.0","spread":null},{"groupId":"OG002","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"14.5","spread":null},{"groupId":"OG002","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"10.2","spread":null},{"groupId":"OG002","value":"15.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"4.3","spread":null},{"groupId":"OG002","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"9.1","spread":null},{"groupId":"OG002","value":"24.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"5.4","spread":null},{"groupId":"OG002","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"4.3","spread":null},{"groupId":"OG002","value":"6.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination","description":"A SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event. Percentage of participants with SAEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) at 1 Month After Vaccination With 20vPnC","description":"OPA titers were measured from serum samples for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the OPA titers and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and 20vPnC only group (20vPnC + saline) as specified in protocol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"609","spread":null},{"groupId":"OG001","value":"573","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1377","spread":null},{"groupId":"OG001","value":"1317","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1449","spread":null},{"groupId":"OG001","value":"1478","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"977","spread":null},{"groupId":"OG001","value":"1102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":null},{"groupId":"OG001","value":"344","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1722","spread":null},{"groupId":"OG001","value":"1531","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2252","spread":null},{"groupId":"OG001","value":"2644","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1875","spread":null},{"groupId":"OG001","value":"1932","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2165","spread":null},{"groupId":"OG001","value":"2211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"709","spread":null},{"groupId":"OG001","value":"640","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1520","spread":null},{"groupId":"OG001","value":"1852","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1059","spread":null},{"groupId":"OG001","value":"846","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"637","spread":null},{"groupId":"OG001","value":"530","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"305","spread":null},{"groupId":"OG001","value":"377","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5225","spread":null},{"groupId":"OG001","value":"4464","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"385","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4907","spread":null},{"groupId":"OG001","value":"5544","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2","description":"IgG levels were measured in serum samples using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length S-binding assay. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in protocol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29114","spread":null},{"groupId":"OG001","value":"26655","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2","description":"The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from before to approximately 1 month after vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in the protocol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":187},"commonTop":["Injection site pain (PAIN)","Fatigue (FATIGUE)","Headache (HEADACHE)","Myalgia (MUSCLE PAIN)","Arthralgia (JOINT PAIN)"]}}}